• Français
  • English

Atlanpole Biotherapies

Atlanpole Biotherapies 


Atlanpole Biotherapies is one of the seven competitiveness french clusters dedicated to health, accredited by the French government in 2005. It gathers 92 companies, 56 research units, 2 Hospital Universities and 1 veterinary school, and has 28 european partners in international collaborations.

It gathers actors on four main areas of excellence: 


  • Immunobiotherapy:

Atlanpole Biotherapies cluster’s historical key focus, immuno biotherapy brings together more than 60 institutions including research and care units, companies, and technology platforms, technical facilities and bio-collections. These resources are devoted to research and innovation on antibodies, vaccines, immunmodulators and adoptive transfer of cells to fight against cancer, inflammation, autoimmune and infectious diseases.


  • Radiopharmaceuticals:

The Pays de la Loire Region has been at the forefront of research on radiopharmaceuticals for over 35 years and, together with the Brittany and Centre regions, it has gathered together a critical mass of expertise and resources including forty research and care institutions, companies, and technology platforms, technical facilities and bio-collections. This scientific community is notably based on high intensity, high energy cyclotron, Arronax, which is dedicated to innovative medical radioisotopes research and production, in order to develop related radiopharmaceuticals and technologies for oncology, neurology and cardiology.


  • Regenerative Medicine :

Within the ecosystem networking of the cluster, restorative and regenerative medicine began by transplant technology whose growth has been marked by the development of innovative solutions, as well as alternatives to the organ shortage, and for the immunological monitoring of transplanted patients. In parallel, new therapeutic approaches have developed (biomaterials, tissue engineering, cell therapy, gene therapy) which apply to diseases of the bone and joints, dermatology, oncology, pneumology, as well as rare, neurodegenerative and cardiovascular diseases.


  • and Innovative technologies for biotherapies:

It constitutes a real toolbox (biomarkers, vectors, medical devices, instrumentation, experimental models, processes, software solutions …) to use alongside therapeutic innovation, in the framework of the 3 Strategic Action Areas (DAS) of the cluster.  

Atlanpole Biotherapies mission is to boost innovation mainly through public/private partnerships and international networking (28 international partnerships).

Part of its actors is working in animal health: veterinary labs, biotech companies, Veterinary School ONIRIS.


Press  Contact :

Pascale Pied : pied@atlanpole.fr